about
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of ViewPathogenesis of minimal change nephrotic syndrome: an immunological conceptTreatment Strategies of Adult Primary Focal Segmental Glomerulosclerosis: A Systematic Review Focusing on the Last Two DecadesImmunologic Changes Implicated in the Pathogenesis of Focal Segmental GlomerulosclerosisEfficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report.The value of delta neutrophil index in young infants with febrile urinary tract infection.Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.Nephrotic syndrome; is rituximab the light at the end of the tunnel in the treatment of adult steroid-dependent minimal change disease and focal segmental glomerulosclerosis?Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.The Influence and Role of Microbial Factors in Autoimmune Kidney Diseases: A Systematic Review.Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review.Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis.Delta neutrophil index (DNI) as a novel diagnostic and prognostic marker of infection: a systematic review and meta-analysis.Primary focal segmental glomerulosclerosis: miRNAs and targeted therapies.Acute kidney injury is associated with microvascular myocardial damage following myocardial infarction.Rituximab for immunologic renal disease: What the nephrologist needs to know.Oncostatin M is a novel inhibitor of TGF-β1-induced matricellular protein expression.Neutrophil extracellular traps (NETs) in autoimmune diseases: A comprehensive review.Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome.Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy.Focal Segmental Glomerulosclerosis: Genetics, Mechanism, and TherapiesHow immunosuppressive therapy affects T cells from kidney transplanted patients of different age: the role of latent cytomegalovirus infection.Neuropilin-1 and neuropilin-2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells.Boon and bane of remission induction with rituximab in ANCA-associated vasculitis: lessons learned from the RAVE-ITN follow-up study.Dabigatran pharmacokinetics--implications for treatment.Induction regimens for ANCA-Associated Vasculitis.Field Synopsis and Re-analysis of Systematic Meta-analyses of Genetic Association Studies in Multiple Sclerosis: a Bayesian Approach.Posterior nutcracker syndrome - a systematic review.Biological Agents and Therapeutic Plasma Exchange: Can They Coexist in the Future?Renal microRNA- and RNA-profiles in progressive chronic kidney disease.Clinical Presentation, Management, and Prognostic Factors of Idiopathic Systemic Capillary Leak Syndrome: A Systematic Review.Therapeutic Plasma Exchange Strategy in Complement-Mediated Diseases: An Overview.Comment on: Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature.Cardiovascular involvement in systemic rheumatic diseases: An integrated view for the treating physicians.Dapsone as a potential treatment option for Henoch-Schönlein Purpura (HSP).Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases.Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides.Extending the spectrum of a chameleon: IgG4-related disease appearing as interstitial nephritis and mimicking anti-neutrophil cytoplasmic antibody-associated vasculitis.
P50
Q26738374-D835197D-8A7A-4532-B042-29993DA922D4Q26747387-3A2CE74B-7B0B-4C63-A356-8FC4BC9F6C89Q26752836-A17C4D04-7D63-469E-A45F-FAC566AD8624Q26753833-A1E50F22-BC62-4B8C-A2C5-021D44B1FFB2Q33419171-7E4E40B4-E7D3-4743-A538-B3F99F0CFF71Q37627873-C0F3F6EE-B360-4F6B-B50D-0588235FF35EQ38206050-9F82C09D-1164-47D5-8C0F-7F80A376CE06Q38305277-F2F7D0E8-F8A0-44DB-B834-7302D84A8634Q38334787-C597EB57-CDB0-4EEB-9401-A9416790EF39Q38404163-A260922B-A0E8-4DB3-B8C4-80BEC8AF31DDQ38528984-1A68C356-0B9F-4F07-B19E-73C953860702Q38575959-A049ACFF-1445-44BA-9FF4-1E87894C2CB7Q38593867-D9FA0DB7-829A-4837-833D-FA74FEB30F21Q38711181-1CDFE3F6-2C4A-4B1A-B689-E58F6D17C6B6Q38804869-A417E2ED-FD52-4BD0-BE3F-26562D1B77A6Q38835773-D766AB77-0631-4BC3-A030-1EA9BAED6E90Q39245887-8FAF808A-0C55-425E-9F3D-9ED25EF371F6Q39494997-3E4DBB9B-9912-41E2-88ED-2517B0B952FEQ40050558-665A9CBE-31B4-4A29-BDFB-7F675D30DF24Q40105398-00E09E98-9D13-451E-B45B-B37F1CCD0294Q41208157-BB5CBFEF-6D64-4230-839D-38BE65A825E2Q41622450-5B14D21C-EF08-4130-AFD7-69AFE18EE88EQ41906236-5FC3D882-6668-48FF-BC35-E0E2F0CC0869Q42270266-CCAA1040-145B-4BD5-BCAE-5956FFE63516Q42459552-B5ECCB50-1705-4380-B632-FCA46E9999DCQ42956266-3E26D1DA-D1DC-437D-913A-A12ECC330F0DQ44771352-CAA1A52A-0A0D-4063-B541-89DC5F7B987FQ46870210-5CF3AF1B-A999-4D27-B011-10495EA3020EQ47567301-10DC5A61-62C9-43B5-9CDC-A56B1A307FBFQ47574094-16651C03-5BFF-4382-A971-8061EBED84F5Q47800187-DD27DDE3-550A-440B-9A29-3AA397AE1EC2Q47890101-D08ACE55-FB9B-4B14-901D-8DA5EEC39118Q47939599-C0024AA0-AB4A-4CD6-9E10-D7B9DB3C7F2BQ48098936-8BF515E5-F336-4ECA-A228-EE2C3F9D9F2AQ49551985-C004FC6E-0AEA-46D9-A807-3FC1B65F5522Q49900854-305CB38B-C5D2-46D0-A483-6D8B01FA98A3Q50063476-5A029F8F-0077-41E2-81D7-3A51FCB22C48Q51034723-A898E896-C337-4664-9E35-575B7E4C125BQ51217371-7F6A624F-23FB-4729-9E36-7C163F4503DCQ53431879-90FA2EAD-22A9-4CA2-8C11-F4307D73B4D6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andreas Kronbichler
@ast
Andreas Kronbichler
@en
Andreas Kronbichler
@es
Andreas Kronbichler
@nl
type
label
Andreas Kronbichler
@ast
Andreas Kronbichler
@en
Andreas Kronbichler
@es
Andreas Kronbichler
@nl
prefLabel
Andreas Kronbichler
@ast
Andreas Kronbichler
@en
Andreas Kronbichler
@es
Andreas Kronbichler
@nl
P106
P21
P31
P496
0000-0002-2945-2946